United States · Federal contract register · Supplier record

BIOCRYST PHARMACEUTICALS INC

Line: Health r&d services; health care services; experimental development (AN13)Register loaded to September 2026Compiled 17 October 2026

BIOCRYST PHARMACEUTICALS INC — United States · Federal contract register · Supplier record: 22 contracts, all years ($340,856,054 · Jan 2007 – May 2026); $16.0M since January 2024 (12 contracts · 2 agencies); — rank in the line (of 102 suppliers · 0.0%); 2 agencies never served ($76.8M on the line without BIOCRYST PHARMACEUTICALS INC).

Assay record ASY-US-0C7GJ9P0TH · Cite as: Assay Systems, “BIOCRYST PHARMACEUTICALS INC: 12 government contracts in the United States since 2024”, https://assay-systems.com/register/us/biocryst-pharmaceuticals-inc/

22
contracts, all years
$340,856,054 · Jan 2007 – May 2026
$16.0M
since January 2024
12 contracts · 2 agencies
—
rank in the line
of 102 suppliers · 0.0%
2
agencies never served
$76.8M on the line without BIOCRYST PHARMACEUTICALS INC

Own record by year

2020 onward
$2.6M
$199K
$56.7K
$15.5M
$389K
$182K
2020202120222023202420252026

Who buys from BIOCRYST PHARMACEUTICALS INC

since January 2024
2agencies
$16.0Mpaid
86.5%top buyer
Department of Health and Human Services86.5%
$13,877,674
Department of Veterans Affairs13.5%
$2,162,057

Won without a rival

2024-02-16 – 2026-05-21
13uncontested awards
87%of its awards
0without a competition
13single bid

BIOCRYST PHARMACEUTICALS INC won 13 of its 15 public contract awards in United States without a rival from 2024-02-16 to 2026-05-21, worth $7.5M: 0 without a competition and 13 after a competition that drew a single bid. 2 buyers awarded it without a rival, the largest Department of Veterans Affairs with 11.

Buyers: Department of Veterans Affairs (11) · Office of Assistant Secretary for Preparedness and Response (2)

Every uncontested award of BIOCRYST PHARMACEUTICALS INC · United States: all uncontested awards

The line

since January 2024
$566Mline value
124contracts
4agencies
102suppliers
70.3%held by top ten

Health r&d services; health care services; experimental development (AN13)

$239M
$109M
$218M
202420252026Jan–Sep
—of 102 suppliers
$0BIOCRYST PHARMACEUTICALS INC in the line
0.0%share of the line

Agencies that buy the line and never bought from BIOCRYST PHARMACEUTICALS INC

2agencies
35contracts
$76,844,808since January 2024
Department of Defense18 contracts
$50,693,667
Department of the Interior17 contracts
$26,151,140

How the line is bought

by value, since 2024
3%no competition
70%one applicant
0of these to BIOCRYST PHARMACEUTICALS INC
Competed, one supplier applied41 contracts
$393,556,081 · 69.5%
Competed, several suppliers applied53 contracts
$155,147,581 · 27.4%
Awarded directly, no competition30 contracts
$17,551,765 · 3.1%

Contracts reaching their end dates

Oct 2026 – October 2027
34contracts
$69,076,959end by October 2027
10end in September 2027 · $35.6M
10in agencies never served · $26.3M
$750K
$1.8M
$69.8K
$1.4M
$1.5M
$13.1M
$186K
$2.0M
$12.6M
$35.6M
Oct 261 contractNov 263 contractsDec 261 contractJan 271 contractFeb 273 contractsMar 2710 contractsMay 271 contractJun 271 contractAug 273 contractsSep 2710 contracts

Suppliers next to it in the line

since January 2024
EREMID GENOMIC SERVICES LLC1 contract · 1 agency
$15,380
GENSCRIPT USA INC1 contract · 1 agency
$13,062
REGENTS OF THE UNIVERSITY OF MICHIGAN1 contract · 1 agency
$5,760
BIOCRYST PHARMACEUTICALS INC
$0

All 102 suppliers in the line

The extract

Every buying office, every contract holder, value, number and end date behind the figures above.

Request extractSee a sample extract

Source: USAspending.gov, U.S. Department of the Treasury, Bureau of the Fiscal Service, usaspending.gov, accessed 30 September 2026.The data is available to copy, adapt, redistribute, or otherwise use for non-commercial or for commercial purposes (USAspending.gov, Licensing); no Dun & Bradstreet data is shown.